Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 26, 2017

DrugPatentWatch Database Preview

Desvenlafaxine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for desvenlafaxine and what is the scope of desvenlafaxine freedom to operate?

is the generic ingredient in four branded drugs marketed by Alembic Pharms Ltd, Osmotica Pharm Corp, Teva Pharms Usa, Sun Pharma Global, Sandoz Inc, Actavis Labs Fl Inc, Lupin Ltd, West-ward Pharms Int, Wyeth Pharms Inc, and Mylan Pharms Inc, and is included in twelve NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for desvenlafaxine. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: desvenlafaxine

Drug Master File Entries: see list16
Suppliers / Packagers: see list3
Bulk Api Vendors: see list58
Clinical Trials: see list15
Patent Applications: see list1,143
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:desvenlafaxine at DailyMed

Tentative approvals for DESVENLAFAXINE

Applicant Application No. Strength Dosage Form
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
West-ward Pharms Int
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204082-001Feb 16, 2016ABRXNoNo► Subscribe► Subscribe
Wyeth Pharms Inc
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-002Feb 29, 2008ABRXYesYes6,673,838► SubscribeY ► Subscribe
Osmotica Pharm Corp
TABLET, EXTENDED RELEASE;ORAL204683-002Jul 10, 2013BCRXNoNo► Subscribe► Subscribe
Lupin Ltd
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204172-002Jun 29, 2015ABRXNoNo► Subscribe► Subscribe
Lupin Ltd
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204172-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus